Clinical Trial

A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)

Name: A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS) — clinical trial record (NCT07698899)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to find out whether 177Lu-DPTA-omburtamab is a safe treatment for children and adolescents with recurrent/refractory medulloblastoma or another type of cancer with CNS metastases.

Trial Details

NCT Number	NCT07698899
Lead Sponsor	Memorial Sloan Kettering Cancer Center Collaborators: Y-mAbs Therapeutics
Conditions	Recurrent Medulloblastoma, Refractory Medulloblastoma, CNS Metastases, Central Nervous System Metastasis
Enrollment	18 participants
Start Date	2026-07-02
Primary Completion	2030-06-02 (estimated)
Study Completion	2030-07-02 (estimated)
Updated on ClinicalTrials.gov	2026-07-13